IJO:毒瘾治疗药物纳曲酮可能对癌症也有效

2016-06-30 佚名 生物谷Bioon.com

来自伦敦大学的研究人员最近发现将用于成瘾治疗的药物纳曲酮(naltrexone)以低剂量治疗癌症病人能带来一些有益治疗效果。   研究人员发现纳曲酮不仅可以阻止癌细胞生长,还能够改变细胞内在机制使癌细胞发生"自杀",这种药物能够帮助其他癌症治疗方法变得更加有效。   文章作者Dr Wai Liu和Angus Dalgleish教授等人发现纳曲酮在小剂量下能够激活促进


来自伦敦大学的研究人员最近发现将用于成瘾治疗的药物纳曲酮(naltrexone)以低剂量治疗癌症病人能带来一些有益治疗效果。
 
研究人员发现纳曲酮不仅可以阻止癌细胞生长,还能够改变细胞内在机制使癌细胞发生"自杀",这种药物能够帮助其他癌症治疗方法变得更加有效。
 
文章作者Dr Wai Liu和Angus Dalgleish教授等人发现纳曲酮在小剂量下能够激活促进癌细胞自杀的基因表达,同时还会影响免疫系统增加对癌细胞的监视和杀伤。
 
Dr Liu这样说道:"我们证明纳曲酮在不同剂量下对基因表达的影响有所不同,我们可以借助这一点找到抗癌新方法。癌症病人不仅希望药物能够阻止癌细胞生长,还希望彻底摆脱癌症。而我们已经看到药物处理两天再将其撤掉,癌细胞就会停止细胞周期并发生细胞死亡。"
 
Dr Liu在癌症治疗领域从事了20年研究,他希望他的研究能够推动纳曲酮在癌症治疗方面的临床应用,并且他还认为纳曲酮与其他癌症治疗方法联合使用可能会具有很好的效果。
 
现在在许多国家纳曲酮都已经得到批准用于戒除酒精成瘾和海洛因成瘾的治疗,但是使用的药物剂量远远高于该项研究所使用的剂量,但是纳曲酮目前还不能用于其他疾病治疗。
 
Dr Liu补充道:"我们选择一种对人类相对安全的药物为其找到了新的用途,在深入了解了药物动力学之后这一切就能成为可能。如果通过这种方式还有多少药物的用途能够得到进一步拓展?"
 
相关研究结果发表在国际学术期刊International Journal of Oncology上。

原始出处:

Liu WM, Scott KA, Dennis JL, Kaminska E, Levett AJ, Dalgleish AG.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=127114, encodeId=d24312e11405, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:26:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126775, encodeId=a174126e754a, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:56:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109652, encodeId=5d4e10965298, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109653, encodeId=b584109653e9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921648, encodeId=cd0e1921648bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Sat May 06 03:50:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92045, encodeId=16fc9204535, content=太厉害了,这两者都能联系起来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Tue Jul 05 21:42:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369840, encodeId=cef713698406e, content=<a href='/topic/show?id=970fe7345d3' target=_blank style='color:#2F92EE;'>#纳曲酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77345, encryptionId=970fe7345d3, topicName=纳曲酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Jul 02 09:50:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
    2016-09-15 1e10c84am36(暂无匿称)

    文章不错,值得拜读

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=127114, encodeId=d24312e11405, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:26:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126775, encodeId=a174126e754a, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:56:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109652, encodeId=5d4e10965298, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109653, encodeId=b584109653e9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921648, encodeId=cd0e1921648bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Sat May 06 03:50:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92045, encodeId=16fc9204535, content=太厉害了,这两者都能联系起来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Tue Jul 05 21:42:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369840, encodeId=cef713698406e, content=<a href='/topic/show?id=970fe7345d3' target=_blank style='color:#2F92EE;'>#纳曲酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77345, encryptionId=970fe7345d3, topicName=纳曲酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Jul 02 09:50:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
    2016-09-14 1e10c84am36(暂无匿称)

    文章不错,值得拜读

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=127114, encodeId=d24312e11405, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:26:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126775, encodeId=a174126e754a, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:56:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109652, encodeId=5d4e10965298, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109653, encodeId=b584109653e9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921648, encodeId=cd0e1921648bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Sat May 06 03:50:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92045, encodeId=16fc9204535, content=太厉害了,这两者都能联系起来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Tue Jul 05 21:42:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369840, encodeId=cef713698406e, content=<a href='/topic/show?id=970fe7345d3' target=_blank style='color:#2F92EE;'>#纳曲酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77345, encryptionId=970fe7345d3, topicName=纳曲酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Jul 02 09:50:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
    2016-09-02 doctorJiangchao

    继续学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=127114, encodeId=d24312e11405, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:26:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126775, encodeId=a174126e754a, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:56:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109652, encodeId=5d4e10965298, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109653, encodeId=b584109653e9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921648, encodeId=cd0e1921648bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Sat May 06 03:50:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92045, encodeId=16fc9204535, content=太厉害了,这两者都能联系起来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Tue Jul 05 21:42:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369840, encodeId=cef713698406e, content=<a href='/topic/show?id=970fe7345d3' target=_blank style='color:#2F92EE;'>#纳曲酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77345, encryptionId=970fe7345d3, topicName=纳曲酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Jul 02 09:50:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
    2016-09-02 doctorJiangchao

    继续关注

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=127114, encodeId=d24312e11405, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:26:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126775, encodeId=a174126e754a, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:56:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109652, encodeId=5d4e10965298, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109653, encodeId=b584109653e9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921648, encodeId=cd0e1921648bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Sat May 06 03:50:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92045, encodeId=16fc9204535, content=太厉害了,这两者都能联系起来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Tue Jul 05 21:42:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369840, encodeId=cef713698406e, content=<a href='/topic/show?id=970fe7345d3' target=_blank style='color:#2F92EE;'>#纳曲酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77345, encryptionId=970fe7345d3, topicName=纳曲酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Jul 02 09:50:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=127114, encodeId=d24312e11405, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:26:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126775, encodeId=a174126e754a, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:56:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109652, encodeId=5d4e10965298, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109653, encodeId=b584109653e9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921648, encodeId=cd0e1921648bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Sat May 06 03:50:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92045, encodeId=16fc9204535, content=太厉害了,这两者都能联系起来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Tue Jul 05 21:42:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369840, encodeId=cef713698406e, content=<a href='/topic/show?id=970fe7345d3' target=_blank style='color:#2F92EE;'>#纳曲酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77345, encryptionId=970fe7345d3, topicName=纳曲酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Jul 02 09:50:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]
    2016-07-05 oo902

    太厉害了,这两者都能联系起来了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=127114, encodeId=d24312e11405, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Thu Sep 15 07:26:00 CST 2016, time=2016-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=126775, encodeId=a174126e754a, content=文章不错,值得拜读, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzdAIB7UwTkHt6fQkBP8ictliaXtc5gCUmYdAW1sAETC2nhO3q6YjRHkUibyOCtP8ibmXNObTyd63A076/0, createdBy=d4111948983, createdName=1e10c84am36(暂无匿称), createdTime=Wed Sep 14 14:56:00 CST 2016, time=2016-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109652, encodeId=5d4e10965298, content=继续学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=109653, encodeId=b584109653e9, content=继续关注, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/jW482SpianMayicTRbRZ5RzfPkmqRTH5rHib5mcib8Wb3QdXjhfOK1UubQL2lictjJFdFJ6Lc3cnnCOSWqxXZ4Kk6y5GdzDoy764R/0, createdBy=156e1644785, createdName=doctorJiangchao, createdTime=Fri Sep 02 12:52:00 CST 2016, time=2016-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1921648, encodeId=cd0e1921648bf, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Sat May 06 03:50:00 CST 2017, time=2017-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=92045, encodeId=16fc9204535, content=太厉害了,这两者都能联系起来了, beContent=null, objectType=article, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=a37a1710612, createdName=oo902, createdTime=Tue Jul 05 21:42:00 CST 2016, time=2016-07-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1369840, encodeId=cef713698406e, content=<a href='/topic/show?id=970fe7345d3' target=_blank style='color:#2F92EE;'>#纳曲酮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77345, encryptionId=970fe7345d3, topicName=纳曲酮)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=25e7304, createdName=snf701207, createdTime=Sat Jul 02 09:50:00 CST 2016, time=2016-07-02, status=1, ipAttribution=)]

相关资讯

PNAS:科学家开发出新方法成功绘制出癌症进展

近日,来自爱丁堡大学等机构的一组研究人员涉及了一种新型的计算机方法来模拟癌症进展,相关研究或为开发新型癌症选择性疗法提供一定线索。研究者Bud Mishra教授表示,我们的工作重点关注多种基因和这些基因突变之间的因果关联,随着肿瘤环境对环境变化产生反应,比如缺氧、细胞运动或免疫反应等,这些基因的突变就会驱动癌症进展。研究者希望这种新型的生物信息学工具可以帮助检测肿瘤起源和发育过程中的规律性,而这或

盘点:揭秘炎症和癌症发生的关联之谜

很多研究都表明,不可控制的炎症往往与肿瘤发生及转移密切相关。而且有越来越多的证据表明,肿瘤相关的炎症能够通过促进血管新生和转移,而且持续性的炎性微环境也能通过触发某些特殊的基因突变来诱发肿瘤产生。如今炎性与肿瘤研究的另一个新的领域:炎性微环境对肿瘤的影响已成为科学家们的研究重点。虽然炎症是我们从疾病和损伤中恢复的一个重要部分,但慢性炎症已知与多种癌症有关,如肺癌、肝癌等;而且许多研究都将慢性炎

Ann Rheum Dis:Ipilimumab、nivolumab增加癌症患者自身免疫性关节和组织病

根据最近发表在风湿病年鉴结果,癌症患者接受ipilimumab或nivolumab单独治疗,或两药联合,其发生自身免疫性关节疾病与组织疾病的风险高于正常。从2012年到2016年,研究人员为13名使用ipilimumab或nivolumab单药治疗或联合治疗的实体瘤患者进行了研究,其中男性占83%,对患者的新风湿病的症状进行了分析。癌症类型包括黑色素瘤、非小细胞肺癌、小细胞肺癌和肾细胞癌。结果显示

PNAS:揭秘炭疽毒素如何治疗癌症

最近,来自美国国家过敏症和传染病研究所等机构的科学家通过研究揭示了,将炭疽毒素蛋白同当前化疗药物相结合帮助消除癌变的肿瘤组织,相关研究发表在了国际杂志PNAS上。炭疽杆菌可以引发致死性的炭疽热,这种细菌会产生一种由三种蛋白组成的特殊毒素,而每一种蛋白却是非毒性的,因为这种蛋白可以被工程化修饰用来抑制肿瘤的生长,因此其或许就可以帮助开发新型的癌症疗法;然而截止到目前为止,科学家们并不确定炭疽毒素蛋白

多篇文献表明父亲“肥胖、高龄、吸烟”,增加后代癌症风险

前几日,《Cell Reports》上一项新研究揭示孕妇高脂肪和高糖饮食容易引发子孙后代的代谢问题,同时研究人员通过小鼠研究首次表明即使在孕前,女性肥胖导致的表观遗传学变异也可通过血液传递至三代以上,从而增加子孙后代患肥胖相关疾病的风险,包括2型糖尿病和心脏病。该研究为孕妇的健康饮食再次敲了一个警钟。其实,不只是母亲饮食对后代健康产生影响,近年来父亲饮食对后代健康的影响也逐渐被文献报道。Nat

Stem Cells:新研究揭示治疗性干细胞离开血管的新机制

来自北卡罗来纳州立大学的研究人员发现干细胞疗法中起治疗作用的干细胞离开血液的方式与大家之前的认识有所不同。研究人员将这一过程称为angiopellosis,对该过程的认知不仅有助于提高我们对干细胞疗法的理解,还对理解癌症转移过程有所帮助。白细胞需要经过白细胞渗出过程(diapedesis)离开血流到达感染部位,在白细胞渗出过程中,白细胞会改变自身形状穿过血管壁。白细胞渗出过程已经得到了充分了解,研